Fortress Biotech Inc and its majority-owned subsidiary Cyprium Therapeutics Inc announced that Cyprium has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 205 million, subject to closing.

The PRV was granted following the approval of Zycubo (copper histidinate, formerly CUTX-101) by the US Food and Drug Administration on January 12, 2026, for the treatment of Menkes disease. Under a prior agreement, Sentynl Therapeutics Inc assumed full responsibility in December 2023 for the development and commercialization of Zycubo. Upon FDA approval, the PRV was issued and immediately transferred to Cyprium in accordance with the transaction terms.

Cyprium remains eligible to receive tiered royalties on net sales of Zycubo, as well as up to USD 129 million in aggregate development and commercial milestone payments from Sentynl. Additionally, Cyprium is obligated to pay 20 Percent of the proceeds from the PRV sale to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health.

Fortress highlighted that the PRV sale follows three FDA approvals over the past 15 months, including Emrosi, Unloxcyt and Zycubo, as well as the recent divestiture of its former subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Ltd.

Cyprium continues to focus on advancing therapies for Menkes disease and related copper metabolism disorders. The company has an ongoing worldwide exclusive license agreement with NICHD to develop and commercialize AAV-ATP7A gene therapy, an adeno-associated virus-based program designed to deliver a functional copy of the defective copper transporter gene in Menkes patients. The AAV-ATP7A program is currently in pre-clinical development and has received FDA Orphan Drug Designation.

The PRV sale transaction remains subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

Fortress Biotech continues to build shareholder value through product revenues, equity holdings, milestone payments and royalty income across its diversified portfolio spanning oncology, dermatology and rare diseases.